搜尋
ProQR Therapeutics NV
PRQR添加自選
1.720USD
-0.060-3.37%
收盤 07-31 16:00（美東）報價延遲15分鐘
228.74M總市值
虧損本益比TTM
關於 ProQR Therapeutics NV 公司
ProQR Therapeutics N.V. is a biotechnology company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Main purpose of the Company is advancement of its Axiomer RNA-editing platform technology. That technology uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unaddressed needs. The Company operates research pipeline that contains of RNA Therapy and AX-0810 Cholestatic Diseases (NTCP).
ProQR Therapeutics NV簡介
公司代碼PRQR
公司名稱ProQR Therapeutics NV
上市日期Sep 18, 2014
CEOde Boer (Daniel Anton)
員工數量166
證券類型Ordinary Share
年結日Sep 18
公司地址Zernikedreef 9
城市LEIDEN
上市交易所NASDAQ OMX - NASDAQ BASIC
國家Netherlands
郵編2333 CK
電話31881667000
網址https://www.proqr.com/
公司代碼PRQR
上市日期Sep 18, 2014
CEOde Boer (Daniel Anton)
ProQR Therapeutics NV公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. Gerard Platenburg, Ph.D.
Mr. Gerard Platenburg, Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
824.39K
--
Mr. Dinko Valerio, Ph.D.
Mr. Dinko Valerio, Ph.D.
Non-Executive Director
Non-Executive Director
725.69K
--
Mr. Bart Filius
Mr. Bart Filius
Non-Executive Independent Director
Non-Executive Independent Director
300.00K
+50.00%
Dr. James Samuel Shannon, M.D.
Dr. James Samuel Shannon, M.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
61.54K
--
Mr. Daniel Anton de Boer
Mr. Daniel Anton de Boer
Chief Executive Officer, Founder, Executive Director
Chief Executive Officer, Founder, Executive Director
--
--
Mr. Rene K. Beukema
Mr. Rene K. Beukema
Chief Corporate Development Officer, General Counsel, Executive Director
Chief Corporate Development Officer, General Counsel, Executive Director
--
--
Ms. Alison F. Lawton
Ms. Alison F. Lawton
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Theresa M. Heggie
Ms. Theresa M. Heggie
Non-Executive Director
Non-Executive Director
--
--
Ms. Sarah Kiely
Ms. Sarah Kiely
Vice President - Investor Relations and Corporate Communications
Vice President - Investor Relations and Corporate Communications
--
--
Ms. Sheila Sponselee
Ms. Sheila Sponselee
Chief People and Operations Officer
Chief People and Operations Officer
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Gerard Platenburg, Ph.D.
Mr. Gerard Platenburg, Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
824.39K
--
Mr. Dinko Valerio, Ph.D.
Mr. Dinko Valerio, Ph.D.
Non-Executive Director
Non-Executive Director
725.69K
--
Mr. Bart Filius
Mr. Bart Filius
Non-Executive Independent Director
Non-Executive Independent Director
300.00K
+50.00%
Dr. James Samuel Shannon, M.D.
Dr. James Samuel Shannon, M.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
61.54K
--
Mr. Daniel Anton de Boer
Mr. Daniel Anton de Boer
Chief Executive Officer, Founder, Executive Director
Chief Executive Officer, Founder, Executive Director
--
--
Mr. Rene K. Beukema
Mr. Rene K. Beukema
Chief Corporate Development Officer, General Counsel, Executive Director
Chief Corporate Development Officer, General Counsel, Executive Director
--
--
常見問題
ProQR Therapeutics NV的前五大股東是誰？
ProQR Therapeutics NV的前五大股東如下：Mr. Gerard Platenburg, Ph.D.
有多少機構持有ProQR Therapeutics NV(PRQR)的股份？
截至2026Q1，共有122家機構持有ProQR Therapeutics NV的股份，合計持有的股份價值約為38.34M，占公司總股份的36.39% 。與2025Q4相比，機構持股有所增加，增幅為-5670621.00。